Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioMark Diagnostics Inc C.BUX

Alternate Symbol(s):  BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring... see more

Recent & Breaking News (CSE:BUX)

BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection

Newsfile November 5, 2024

BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN

Newsfile September 24, 2024

BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection

Newsfile September 10, 2024

Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Newsfile August 26, 2024

The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay

Newsfile July 31, 2024

BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference

Newsfile July 15, 2024

BioMark Announces Warrant Extension and Granting of Options

Newsfile April 18, 2024

BioMark to Advance Development of Cancer Treatment for Glioblastoma

Newsfile April 9, 2024

BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities

Newsfile February 28, 2024

Theresa Peterson Joins Biomark's Advisory Team

Newsfile February 26, 2024

BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement

Newsfile December 29, 2023

BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay

Newsfile December 4, 2023

BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

Newsfile November 28, 2023

BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives

Newsfile November 14, 2023

BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test

Newsfile November 7, 2023

BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium

Newsfile October 24, 2023

BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team

Newsfile August 30, 2023

Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay

Newsfile August 8, 2023

BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update

Newsfile July 25, 2023

BioMark unveils significant scientific lung cancer research advancements at ASCO 2023

Jonathon Brown June 5, 2023